Vaults have been suggested to play a direct role in multidrug resistance (MDR) to anticancer drugs. The human major vault protein (MVP) also known as lung resistance-related protein (LRP) represents the predominant component of vaults that may be involved in the defense against xenobiotics. Here, we demonstrate that besides MDR-related cytostatics, also the non-MDRrelated drug 5-fluorouracil (5-FU) was able to induce MVP mRNA and protein expression. Treatment with 5-FU amplified the binding activity and interaction of the transcription factor Y-box binding protein-1 (YB-1) with the Y-box of the human MVP gene promoter in a timedependent manner. 5-FU also induced reporter expressions driven by a panel of newly generated MVP promoter deletion mutants. Interestingly, stably YB-1 overexpressing cell clones showed enhanced binding of YB-1 to the Y-box motif, associated with enhanced basal as well as 5-FU-inducible MVP promoter-driven reporter expressions. Moreover, transduction of YB-1 cDNA led to increased expression of endogenous MVP protein. Under physiological conditions, we observed a strong coexpression of MVP and YB-1 in human colon carcinoma specimen. In summary, our data demonstrate a direct involvement of YB-1 in controlling basal and 5-FUinduced MVP promoter activity. Therefore, YB-1 is directly linked to MVP-mediated drug resistance.
Introduction
Multimeric vault particles have been suggested to contribute to resistance towards anticancer drugs. Vault particles consist of the major vault protein (MVP), also known as lung resistance-related protein (LRP), a telomerase-associated protein, a vault-poly (ADPribose) polymerase, and small untranslated RNA (Scheper et al., 1993; Scheffer et al., 1995 Scheffer et al., , 2000 . The distribution of MVP in normal human tissues is similar to other drug resistance-related proteins, with high expression in tissues chronically exposed to xenobiotics. MVP expression was also detected in a variety of clinical specimens; in fact, MVP levels are high in certain multidrug resistant tumors, such as colon carcinomas (Izquierdo et al., 1996a; Pohl et al., 2001) . Increased MVP expression represents an early event in colorectal carcinogenesis (Meijer et al., 1999) . In women with breast cancer, MVP levels have been found to be linked to clinical outcome (Pohl et al., 1999; Schneider et al., 2001) . Increased levels of MVP were present in intrinsically multidrug resistant cancer cell lines, including those derived from colon or breast cancers (Izquierdo et al., 1996b; Laurencot et al., 1997; Kickhoefer et al., 1998; Kitazono et al., 1999) , but also in those selected with the anticancer drugs doxorubicin, mitoxantrone, etoposide, vincristine, cytarabine, cisplatinum, and bleomycin (e.g. Wyler et al., 1997; Komarov et al., 1998; Berger et al., 2000; Cheng et al., 2000; Hu et al., 2002; Meschini et al., 2002) . Thus, vaults are suggested to be involved in the defense against xenobiotics (Mossink et al., 2003) .
Exposure of cells to other stresses, for example hyperthermia, is also associated with an induction of MVP expression (Stein et al., 2002) . In contrast, exposure of cells to certain cytokines such as tumor necrosis factor-alpha caused a repression of MVP gene activity (Stein et al., 1997) .
We have reported previously that a 1.9 kb fragment of the MVP gene promoter displays basal promoter activity (Lange et al., 2000) . The MVP promoter lacks a TATA box, but is characterized by the presence of binding sites for several transcription factors. The promoter contains an inverted CCAAT-box, also termed Y-box, a recognition site for the transcription factor Y-box binding protein-1 (YB-1), which responds to environmental stresses such as anticancer drugs, UV light, and hyperthermia (Asakuno et al., 1994; Ohga et al., 1996 Ohga et al., , 1998 Ise et al., 1999; Stein et al., 2001 ).
Correlation of nuclear localization of YB-1 and intrinsic expression of the multidrug resistance gene 1 (MDR1) has been shown in mammary carcinomas and osteosarcomas (Bargou et al., 1997; Oda et al., 1998) .
Since MVP expression is induced after exposure to a variety of MDR-associated anticancer drugs including the antimetabolite cytarabine, and since 5-fluorouracil (5-FU) has been the mainstay of chemotherapy for colorectal cancer, we investigated whether the non-MDR-related drug 5-FU is able to modulate MVP expression. We are the first to show that besides MDRassociated drugs such as adriamycin and vincristine, 5-FU is also able to induce the expression of MVP. Moreover, we show specific interactions of YB-1 with the Y-box binding motif of the MVP promoter and enhanced binding of YB-1 in stably YB-1 transduced clones. Interestingly, treatment with 5-FU led to increased binding of YB-1 to the Y-box of the MVP promoter in a time-dependent manner. Furthermore, transduction of YB-1 cDNA led to increased expression of endogenous MVP protein. Under physiological conditions, we observed a strong coexpression of the proteins MVP and YB-1 in human colon carcinoma specimen. Our results demonstrate that YB-1 facilitates basal and 5-FU-induced MVP activity. Therefore, YB-1 is directly linked to MVP expression and thus contributes to MDR.
Results

Induction of MVP gene-and protein expression by anticancer drugs
We observed transcriptional activation of the MVP gene after treatment with adriamycin, 5-FU, vincristine, and cisplatinum in human colon carcinoma HCT116 cells by quantitative real-time RT-PCR ( Figure 1) . Adriamycin led to a more than two-fold enhancement of MVP mRNA expression, whereas 5-FU caused a more than five-fold increase in MVP mRNA. MVP expression was induced within several hours after exposure to cytostatics irrespective of their chemical composition. However, the time course of maximal MVP mRNA synthesis was apparently drug-specific as shown for adriamycin and 5-FU (Figure 1a , c). Treatments with vincristine and cisplatinum also induced MVP mRNA 1.5-or 2-fold, respectively (data not shown). 2, 3, 4, 5, 6, 12, 24, 48, 72, 96 and 120 h after exposure to adriamycin (a) or 1, 2, 3, 4, 5, 6, 24, 48, 72, 96 , and 120 h after exposure to 5-FU (c); values depicted represent the ratios of MVP and G6PDH expression, expressed as percentage of the untreated parental HCT116 cells (100%). RT-PCR was performed as two step reaction using gene-specific primers and hybridization probes in the PCR step. (b,d) Immuno flow cytometry for MVP, monitored 1, 2, 3, 4, 5, 6, 12, 24, 48, 72, 96 and 120 h after exposure to adriamycin (b) or 1, 2, 3, 4, 5, 6, 24, 48, 72, 96 , and 120 h after exposure to 5-FU (d) using the two monoclonal antibodies LRP-56 (~) and LMR-5 ('); values depicted represent the differences of the mean fluorescence/cell for MVP and the mean fluorescence/cell for the secondary fluorescein-labeled antibody, expressed as percentage of the untreated parental HCT116 cells (100%)
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In parallel, we analyzed whether MVP gene activation is correlated with MVP protein synthesis by immuno flow cytometry. MVP levels increased significantly in HCT116 cells after treatment with anticancer drugs: 11-fold with adriamycin (P ¼ 0.0286; Figure 1b) , twofold with 5-FU (P ¼ 0.0286; Figure 1d ), 10-fold with vincristine, and three-fold with cisplatinum (data not shown). In summary, our results indicate that exposure of HCT116 cells to anticancer drugs leads to transcriptional activation of the MVP gene, and in consequence to a significant increase of the level of MVP protein, which is involved in the MDR phenotype of certain cancer cells.
Interaction of the transcription factor YB-1 with the human MVP promoter
We previously identified several putative consensus sequence motifs for transcription factors within the MVP promoter (Lange et al., 2000) , including a Y-box motif at position À279 to À275 upstream of the transcriptional initiation site. To investigate the role of YB-1 in MVP gene regulation, we examined whether YB-1 is able to bind to the Y-box motif of the MVP promoter. Nuclear extracts of human colon carcinoma HCT116 cells were analysed by EMSA using a singlestranded Y-box oligonucleotide derived from the MVP promoter ( Figure 2a) . A major retarded DNA : protein complex was observed in HCT116 cells (lane 1). Preincubation with a molar excess of unlabeled oligonucleotides comprising the Y-box abolished formation of the major retarded complex (lanes 2,3). An identical result was obtained by using another unlabeled oligonucleotide derived from the MDR1 promoter also containing the Y-box motif (lanes 4,5). A unlabeled unrelated oligonucleotide derived from the cyclin E promoter failed to influence the formation of retarded DNA : protein complexes (lanes 6,7). Incubation with an affinity-purified polyclonal peptide antibody specific for YB-1 reduced the formation of the major retarded complex (lanes 8,9), whereas incubation with an control antibody (b-tubulin) had no effect (lanes 10,11). These data demonstrate, that YB-1 specifically interacts with the Y-box motif in the MVP promoter.
Increased binding of YB-1 to the human MVP promoter after treatment with 5-FU Next, we investigated the binding of YB-1 to the Y-box of the human MVP promoter in HCT116 cells after treatment with 5-FU, since MVP induction at the RNA and protein levels by 5-FU treatment has already been shown (Figure 1c, d ). When using the nuclear extracts of untreated and 5-FU-treated HCT116 cells and the single-stranded Y-box sequence as a probe, a major retarded MVP-Y-box oligo : YB-1 complex was seen ( Figure 2b , lanes 1-6). Increased DNA : YB-1 binding was observed after 1, 2, and 3 h of treatment with 5-FU. By densitometry, enhanced integrated densitiy values have been determined for these time points with highest up to two-fold elevations after 2 h of 5-FU treatment. Interestingly, the intensity of this signal was most increased when nuclear extracts from cells treated for 2 h with 5-FU were employed (lane 3). At this time point after 5-FU treatment, we previously observed an induction of MVP mRNA (Figure 1c ). Using the nuclear extract from the 2 h treatment with 5-FU, preincubation with a molar excess of the unlabeled oligonucleotide comprising the Y-box again abolished formation of the major retarded complex (lanes 7,8) . Incubation with the YB-1 antibody again reduced the formation of the major retarded complex (lanes 9,10), whereas incubation with the btubulin antibody had no effect (lanes 11,12 ). These data demonstrate that 5-FU treatment of HCT116 colon carcinoma cells is associated with increased DNA binding activity of YB-1 in response to 5-FU exposure. Thus, YB-1 represents an important transcription factor controlling MVP promoter activity in response to treatment with 5-FU.
Impact of YB-1 on basal and 5-FU induced human MVP promoter activity
Since a specific interaction of the transcription factor YB-1 with the human MVP promoter could be demonstrated (Figure 2) , we investigated the effect of YB-1 overexpression on MVP promoter activity. We have previously created a stably YB-1-transduced cell line (HBL100/YB-1) which overexpresses YB-1 (Stein et al., 2001 ). First we analysed whether YB-1 overexpression is associated with increased nuclear binding activity of YB-1. Nuclear extracts of HBL100 and of HBL100/YB-1 cells were analysed by an EMSA using a single-stranded Y-box oligonucleotide derived from this region ( Figure 3) . A major retarded DNA : protein complex was observed in the HBL100 cells (lane 1). However, this complex was more prominent in HBL100/YB-1 cells, indicating a higher YB-1 concentration in HBL100/YB-1 cells (lane 2). Preincubation with a molar excess of the unlabeled oligonucleotides comprising the Y-box from the MVP promoter (lanes 3,4) or from the MDR1 promoter (lanes 5,6) abolished formation of the major retarded complex, whereas the unrelated oligonucleotide derived from the cyclin E promoter failed to influence the formation of retarded DNA : -protein complexes (lanes 7,8) . Incubation with the YB-1 antibody reduced the formation of the major retarded complex (lanes 9,10), whereas incubation with the btubulin antibody showed no influence (lanes 11,12). We conclude, that overexpression of YB-1 in the HBL100/ YB-1 cells leads to increased binding to the Y-box motif in the MVP promoter.
For a more detailed analysis of the transcriptional regulation of the human MVP promoter by YB-1, pCAT-MVP promoter deletion mutants were generated using our previously isolated 1881 bp long MVP promoter fragment (MVP1.9) (Lange et al., 2000) . Schematic drawings of the reporter constructs pCAT-MVP1.9, pCAT-MVP0.7, pCAT-MVP0.3, and pCAT-MVP0.13 are shown in Figure 4a .
Overexpression of YB-1 in HBL100/YB-1 cells was associated with a strong increase in MVP promoter-driven CAT reporter expression when compared to HBL100 cells (P ¼ 0.0286; Figure 4b ). Thus, highest six to eight-fold increases in CAT expression were observed in HBL100/YB-1 cells vs HBL100 cells after transfection with the MVP promoter constructs pCAT-MVP1.9, pCAT-MVP0.7, and pCAT-MVP0.3, which contain the Y-box binding motif ( Figure 4c ). unlabeled MVP-Y-box oligo, 50 Â , 100 Â ; lanes 4,5: unlabeled MDR1-Y-box oligo, 50x, 100x; lanes 6,7: unlabeled cyclin E oligo, 50 Â , 100 Â ; lanes 8,9: YB-1-specific antibody, 1, 2 mg; lanes 10,11: b-tubulin-specific antibody, 1, 2 mg. (b) Increased binding of YB-1 to the MVP-Y-box oligo after treatment with 5-FU. Lane 1: nuclear extract of untreated HCT116 cells; lanes 2-6: nuclear extracts of HCT116 cells treated with 5-FU for 1,2,3,4, and 5 h; lanes 7-12: nuclear extract of HCT116 cells treated with 5-FU for 2 h; lanes 1-12: Biotin-endlabeled MVP-Y-box oligo; lanes 7,8: unlabeled MVP-Y-box oligo, 50 Â , 100 Â ; lanes 9,10: YB-1-specific antibody, 1, 2 mg; lanes 11,12: b-tubulin-specific antibody, 1, 2 mg YB-1 mediates transcriptional regulation of MVP U Stein et al Next, we analysed whether YB-1 is involved in MVP gene activation in response to treatment with 5-FU. We found that 5-FU treatment of HBL100 cells, transiently transfected with the pCAT-MVP promoter mutants, resulted in elevated CAT expression (P ¼ 0.0286; Figure 4b ). 5-FU-induced CAT expressions of about three-fold were determined with the constructs pCAT-MVP1.9, pCAT-MVP0.7, and pCAT-MVP0.3. With pCAT-MVP0.13, the promoter construct lacking the Y-box, no 5-FU-caused reporter expression was observed ( Figure 4d ).
In parallel, we also used HBL100/YB-1 cells as recipients for our MVP promoter deletion constructs. 5-FU treatment led to 1.5-to 2-fold increases of expression of the CAT reporter gene with the pCAT-MVP1.9, pCAT-MVP0.7, and pCAT-MVP-0.3 (Figure 4b ). No increase was seen when using the Y-box-less construct pCAT-MVP0.13. When summarizing the effects of YB-1 transduction and of 5-FU treatment, highest inductions of CAT expressions were observed (P ¼ 0.0286; Figure 4b ). With the Y-box-harboring constructs pCAT-MVP1.9, pCAT-MVP0.7, and pCAT-MVP0.3, reporter inductions of 9 to 12-fold were determined (Figure 4e ).
These results demonstrate that YB-1 is involved in regulating drug-induced MVP promoter activity and that MVP promoter activation in response to drug treatment is largely dependent on the availability of YB-1 in these cells.
Time course of YB-1-dependent induction of human MVP promoter activity after 5-FU treatment
We have demonstrated that 5-FU treatment amplifies the DNA binding activity of YB-1. Next, pCAT-MVP0.7
pCAT-MVP0.3
pCAT-MVP0.13
CAT expression / fold increase Overexpressed YB-1 can activate endogenous MVP protein expression
To analyse whether increased levels of YB-1 can activate the endogeneous MVP gene we transduced YB-1 cDNA (pcDNA6/YB-1) into HCT116 cells and determined MVP expression at the protein level by immuno flow cytometry by using the monoclonal MVP-specific antibody LMR-5 (Figure 6a ). Endogenous MVP expression was elevated after transduction of the YB-1-expressing pcDNA6/ YB-1 expression cassette. We observed a two-fold and a 3.5-fold increase in endogenous MVP protein in the YB-1-transduced cells four and five days after YB-1 transduction, compared to non-transduced parental cells (Figure 6b ). These data demonstrate that YB-1 is an important transcriptional regulator of the MVP gene.
Coexpression of MVP and YB-1 in human colon carcinomas
Since specific interactions with the MVP promoter were shown for YB-1 in the in vitro systems, we next examined the expression of MVP and YB-1 in human colon carcinomas obtained from previously untreated patients by immunohistochemistry. Interestingly, a coexpression of MVP and YB-1 was observed in all tumors analysed: Moderate to strong MVP and YB-1 staining was observed in four out of five patients (Figure 7 , as examplified for representative tumors). The staining was cytoplasmic and present in epithelial cells in both normal regions as well as in cancerous parts of the sections. One tumor showed very weak stainings of both MVP and YB-1. Immunohistochemical stainings were controlled by using the respective isotype antibody for consecutive sections (Figure 7c, f, i) These results demonstrate a strong coexpression of MVP and YB-1 in the normal epithelial cells as well as in the cancerous parts of the tissue sections throughout the panel of the tumors analysed. 
Discussion
The Y-box binding protein YB-1 is a well-established transcription factor (Holm et al., 2002; Kohno et al., 2003; Kuwano et al., 2003) . It was shown that its intracellular localization changes from cytoplasmic to nuclear after drug treatment, UV light irradiation, and hyperthermia (Asakuno et al., 1994; Ohga et al., 1996 Ohga et al., , 1998 Ise et al., 1999; Stein et al., 2001) . YB-1 can bind to damaged DNA suggesting that it may act as a stress sensor (Hasegawa et al., 1991) . The present data add to our recent reports that showed that YB-1 controls activity of the MDR1 and the MRP1 gene (Bargou et al., 1997; Stein et al., 2001) . We have shown here that YB-1 facilitates basal and drug-induced transcriptional activity of the MVP gene. MVP is associated with a drug resistance phenotype of certain malignant tumors. These results demonstrate that YB-1 is also directly involved in MVP-mediated drug resistance. These findings are in line with data from a clinical study where it was shown that YB-1 predicts drug resistance and poor patient outcome independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1 in women with breast cancer (Janz et al., 2002) .
After exposure to anticancer drugs, MVP expression was enhanced at both, the transcriptional as well as at the translational level. These data confirm published reports concerning adriamycin-induced MVP expression (Wyler et al., 1997; Cheng et al., 2000; Berger et al., 2000; Meschini et al., 2002) . However, we are first to show that also the non-MDR-related drug 5-FU induces MVP gene expression. We investigated timedependent MVP induction kinetics for several anticancer drugs (Figure 1 ) and found them to be drug specific. These findings are supported by a report of Komarov et al. (1998) , which describes a rapid induction of MVP expression by the antimetabolite cytarabine. In addition, it was shown that drug resistant, doxorubicin-selected cell lines expressed increased MVP levels and developed 5-FU resistance by a mechanism described as independent of MDR1, MRP1, MRP2, and breast cancer resistance protein (Hu et al., 2002) . 5-FU has been the mainstay of chemotherapy for colorectal cancer for four decades (Tebbutt et al., 2002) . Since MVP expression is an early and frequent event in colorectal carcinogenesis (Meijer et al., 1999) , the presently described mechanism of 5-FU-induced MVP expression should add to the understanding of the frequently occuring clinical nonresponsiveness to 5-FU in patients (Midgley and Kerr, 1999) . When we first identified the human MVP promoter, it revealed the presence of several binding motifs for transcription factors such as binding sites for p53 and SP1, and furthermore an inverted CCAAT binding motif for YB-1 (Lange et al., 2000) . To identify whether the Y-box motif is involved in regulating MVP gene activity, we analysed the interaction of YB-1 with the Y-box of the MVP promoter by EMSA. We showed that YB-1 specifically interacts with this sequence motif in different cell lines (Figures 2,3) . Moreover, binding of YB-1 to the MVP promoter Y-box motif was increased in stably YB-1-transduced cell clones (Figure 3 ) compared to the nontransduced parental cells. Furthermore, we found that exposure to the drug 5-FU led to enhanced binding of YB-1 to the Y-box in a time-dependent manner (Figure 2b) underlining the involvement of YB-1 in regulation of MVP activity.
In order to determine the influence of YB-1 on basal and 5-FU-induced MVP promoter-driven expression, we performed CAT reporter assays. These analyses revealed that the basal promoter activity of a panel of four MVP promoter deletion mutants showed no linear promoter activity in reporter assays with respect to their length (Figure 4) . Thus, the shorter MVP0.7 variant was found to be clearly higher than that of the long MVP1.9 variant. These results point to the assumption that the longer variant may carry regulatory motifs that negatively interfere with the positive regulation of MVP, for example, such as overlapping Sp1/WT1 sites, binding sites for fos and numerous sites for GR, which were found within that part of the MVP promoter sequence. These elements have been described as possible negative regulatory elements for the promoter activity of the MDR1 gene (Labialle et al., 2002; Scotto, 2003) . Thus, it might be hypothesized that these elements within the -1859 to -680 MVP promoter sequence might also contribute to the promoter activity of the MVP gene resulting in lower CAT expression which we determined in our reporter system. The findings, that promoter fragments show no linear promoter activity in reporter assays with respect to their length, are not unusual. Such effects have also been described for the promoter activity of other, for example, drug resistance-associated genes MDR1 (Kohno et al., 1989; Comerford et al., 2002) , and GSTM2 (Kumar and Reddy, 2001 ). Interestingly, a recently published report using comparable deletion mutants of the MVP promoter described almost identical levels of basal reporter expression (Steiner et al., 2004) .
Our reporter assays demonstrated that particularly those promoter constructs harbouring the Y-box were YB-1-as well as 5-FU-responsive. These data clearly show that YB-1 can activate the MVP promoter most likely through the Y-box. The remaining promoter construct, which lacks a Y-box, did also show enhanced CAT protein level although to lesser extent (when comparing YB-1-overexpressing cell line to the parental cell line). This finding points to the assumption that YB-1 may not exclusively bind to the Y-box, but may also bind directly or via interaction with other transcription factors to other motifs within the proximal MVP promoter, for example, to the p53 binding site (Okamoto et al., 2000) . Interactions of YB-1 and p53 in regulation of gene expression of different genes were reported in several studies (Okamoto et al., 2000; Mertens et al., 2002; Zhang et al., 2003; Lasham et al., 2003) .The p53 binding site is GC-rich and binding of YB-1 to other non-Y-box, but GC-rich sequences, has been previously reported (Stein et al., 2001) . More importantly, a recent publication determined all possible YB-1 recognition sequences and pointed out that YB-1 specifically interacts with GC-rich recognition sequences reminiscent of those in the p53 element .
Our study clearly demonstrates that YB-1 is involved in 5-FU-induction of MVP expression, determined by increased reporter expressions and by increased binding of YB-1 to the MVP-Y-box oligo after 5-FU treatment (Figures 4, 5, 2b ). This is supported by Zhang et al. (2003) , showing that treatment of tumor cells with cytostatics, including non-MDR-drugs, led to nuclear accumulation of YB-1, representing the essential prerequisite for binding of YB-1 to specific DNA binding motifs.
In order to prove the decisive role of YB-1 in controlling endogenous MVP expression, we transduced YB-1 into human colon carcinoma cells and measured a more than three-fold elevation of MVP protein ( Figure 6) . These data clearly demonstrate that YB-1 is not only involved in the regulation of other drug resistance-associated genes such as MDR1 and MRP1 (e.g. Bargou et al., 1997; Oda et al., 1998; Stein et al., 2001) , but is also directly involved in the regulation of MVP.
Since overexpression of YB-1 is reported for e.g. human colorectal carcinomas (Meijer et al., 1999; Shibao et al., 1999) , we further analysed the biological relevance of our findings in these human tumors (Figure 7) . The strong coexpression of MVP and YB-1 was observed in all human colon carcinomas examined. These results underline the role of YB-1 to regulate the expression of MVP also under physiological conditions.
Recently, reports were published indicating a role for chromatin remodeling in the regulation of MVP (Emre et al., 2004) and describing the impact of SP-transcription factors in basal MVP promoter activity (Steiner et al., 2004) . Our data broaden the knowledge on MVP gene regulation by the direct involvement of YB-1 in YB-1 mediates transcriptional regulation of MVP U Stein et al controlling basal and 5-FU induced MVP promoter activity and MVP expression. Therefore, YB-1 is directly linked to MVP mediated drug resistance. These observations provide a biological rationale for interference approaches aimed at identifying compounds designed for circumvention/reversal of drug resistance in human tumors.
Materials and methods
Tumor cell lines and drug treatment
The human colon carcinoma cell line HCT116 and the human breast epithelial cell line HBL100 were cultured as described previously (Stein et al., 2001) . The adriamycin-selected and MVP-overexpressing human lung carcinoma cell line GLC-4/ ADR was provided by Rik J Scheper, Free University Amsterdam, The Netherlands (Zijlstra et al., 1987) .
Drug treatment was performed with adriamycin (1000 ng/ml in HCT116; Pharmacia Biotech, Freiburg, Germany), 5-FU (2000 ng/ml in HCT116, and 1500 ng/ml in HBL100; Ribosepharm, Mu¨nchen, Germany), cisplatinum (2000 ng/ml in HCT116; Ribosepharm), and vincristine (5 ng/ml in HCT116; Eli Lilly, Gieen, Germany). All drug concentrations were below the IC 50 of the respective cell line.
Generation of stably transduced V5 tagged YB-1-expressing HBL100 cells YB-1 cDNA was removed from pUC19 using EcoRI and inserted into the EcoRI site of the pcDNA6 vector (Invitrogen, Groningen, The Netherlands) ensuring in-frame positioning with the V5-histidine tag of pcDNA6 (pcDNA6/YB-1) (Stein et al., 2001) . HBL100 cells were transduced with pcDNA6/ YB-1 using lipofectamin (Gibco BRL, Karlsruhe, Germany), and stably YB-1-transduced HBL100 cells were selected with 5 mg/ml blasticidine (Invitrogen). Expression of recombinant YB-1 was analysed by Western blot using monoclonal antibodies against the V5 tag (Invitrogen) (Ju¨rchott et al., 2003) .
Relative quantitative two-step real-time RT-PCR
Total RNA was isolated by using Trizol reagent (Invitrogen). Reverse transcriptase reaction (RT) was performed with 50 ng of total RNA. Each quantitative real-time PCR (951C for 30 s, 45 cycles of 951C 10s, 621C 10 seconds, 721C 10 s) was performed using the LightCycler (LightCycler DNA Master Hybridization Probes kit, Roche Diagnostics, Mannheim, Germany) as described (Stein et al., 2002) . Expression of MVP and of the house-keeping gene glucose-6-phosphate dehydrogenase (G6PDH) was determined in parallel from the same RT reaction, each performed in duplicate per sample. For MVP, a 114 bp amplicon, and for G6PDH, a 113 bp amplicon was produced, which were detected by gene-specific fluorescein-and LCRed640-labeled hybridization probes (syntheses for MVP: BioTeZ, Berlin, Germany and Tib Molbiol, Berin, Germany; syntheses for G6PDH: Roche Diagnostics). The calibrator cDNA derived from GLC-4/ ADR cells was employed in serial dilutions simultaneously in each run.
Immuno flow cytometry
Incubations with the monoclonal MVP-specific antibodies LRP-56 and LMR-5 (both 1 : 20) and with the secondary goatanti-mouse (for LRP-56) or rabbit-anti-rat (for LMR-5) fluorescein-conjugated antibodies (1 : 50; Sigma, Taufkirchen, Germany) were performed for 60 min on ice as described (Stein et al., 1997) . Fluorescence intensity of 1 Â 10 4 cells was expressed as mean fluorescence/cell (CellQuest program, Becton Dickinson, Heidelberg, Germany). Values depicted represent the differences of the mean fluorescence/cell for MVP and for the secondary fluorescein-labeled antibody.
Electrophoretic mobility shift assay (EMSA) Nuclear extracts were prepared using an extraction kit (Pierce Biotechnology, Rockford, IL). EMSA was performed using the LightShift Chemiluminescent EMSA kit (Pierce Biotechnology). In all, 3 mg of each nuclear extract was incubated for 30 min with the biotin-endlabeled oligonucleotide derived from the human MVP promoter À307 to À248 Biotin-5 0 -AGGGAGAGGCA GAATTGTACTCACCCAGATTGGAAAATGAAAGCCAG ATGGGTAGAGGTG-3 0 (Y-box À279 to -275 underlined; synthesis BioTez, Berlin, Germany). Unlabeled oligonucleotides were used to control the binding specificity, respectively: For MVP-Y-box, the 5 0 -AGGGAGAGGCAGAATTGTACT CACCCAGATTGGAAAATGAAAGCCAGATGGGTAGA GGTG-3 0 oligonucleotide, derived from the human MVP promoter sequence À307 to À248 (MVP-Y-box À279 to À275) was employed. The oligonucleotide 5 0 -CCGGGAGCAGT CATCTGTGGTGAGGCTGATTGGCTGGGCAGGAACA GCGCCGGGGCGTGG-3 0 , derived from the human MDR1 promoter sequence À106 to À47 (MDR1-Y-box À78 to À74) was used as a Y-box-specific competitor. The Y-box-less oligonucleotide, derived from the human cyclin E gene promoter, served as unrelated competitor. For supershift experiments, a YB-1-specific polyclonal antibody was employed (Janz et al., 2002) . The b-tubulin monoclonal antibody was used as unrelated antibody (Becton Dickinson). The DNA : protein complexes were resolved by 6% polyacrylamide gel electrophoresis, blotted, crosslinked, and chemiluminescence was detected.
Cloning of MVP promoter mutants into chloramphenicol acetyltransferase (CAT) reporter plasmid
For cloning of the 1.9 and 0.7 kb fragment of the promoter, the fragments were taken from pCR-MVP1.9 and pCR-MVP0.7 by SpeI/XbaI digestion and inserted into the XbaI site of pCATBasic plasmid (promoter-less; Promega, Madison, WI, USA) resulting in the pCAT-MVP1.9 (À1859 to þ 22) and pCAT-MVP0.7 (À680 to þ 22) constructs. To create the pCAT-MVP0.13 mutant (À130 to þ 22), the PstI promoter fragment was taken from pCAT-MVP1.9 and inserted into the PstI site of pCAT-Basic. For construction of the pCAT-MVP0.3 mutant, the promoter sequence from À310 to þ 1 was PCR-amplified from the pCR-MVP1.9 construct and inserted into the HindIII/ XbaI sites of the pCAT-Basic plasmid. All promoter constructs were sequenced (InViTek, Berlin, Germany).
CAT reporter-enzyme-linked immunosorbent assays (ELISA)
The CAT reporter plasmids containing the MVP promoter deletion mutants were used for transient transfection into HBL100 cells as well as in stably YB-1-transduced HBL100 cells. The plasmids pCAT-Basic (promoterless; Promega), pCAT-control (SV40-promoter; Promega), and transfections w/o DNA served as external controls. Transfer efficiency was controlled by transfection of pCMVb (harboring the b-galactosidase reporter gene; Clontech, Heidelberg, Germany) as internal control. Transfections were performed as described (Stein et al., 2001 ).
For drug induction experiments in HBL100 and HBL100/ YB-1 cells, treatment with 5-FU was started 72 h after transfection for 120 h. ELISAs for CAT and for b-galactosidase were carried out as described previously (Stein et al., 2001) . The amount of CAT protein was normalized to the pCAT-Basic values, to the protein content of the respective lysate, as well as to the internal transfection control of pCMVb (b-galactosidase), and was expressed as pg CAT/mg protein.
pTimer-1 reporter assay
For the analysis of the time course of human MVP promoter activitiy, the pTimer-1-plasmid (Clontech) was employed. To create the pTimer-MVP0.7 (-680 to þ 22) variant, the pCAT-MVP0.7 plasmid was digested with XhoI/BamHI and the promoter fragment was inserted into the XhoI/BamHI sites of pTimer-1. pTimer-MVP0.7 was used for transient transfection into stably YB-1-transduced HBL100 cell clones. The plasmids pTimer-1 (promoter-less) and transfections w/o DNA served as controls.
Treatment with 5-FU (1500 ng/ml) was started 24 h after transfection for another 168 h. Microphotographs were taken at 24, 48, 56, 72, 144 , and 168 h of exposure to 5-FU for green and red fluorescence (Leica, Wetzlar, Germany).
Human tumors and immunohistochemistry
Archival paraffin blocks from formalin-fixed chemotherapynaive human colon carcinomas were from the VU Medical Center, Amsterdam, the Netherlands, and were treated according to the institutional guidelines for handling of patient material. Sections were deparaffinized and rehydrated. Endogenous peroxidase activity was blocked using 0.3% H 2 O 2 in methanol for 30 min. Antigens were detected after heat mediated antigen retrieval methods using 0.01 M citric acid (pH 6.0) in distilled water. During retrieval, slides for YB-1 and MVP detection were placed for 10 min in a microwave. The slides were blocked using 2% appropriate normal serum (rabbit or swine) in PBS/1% BSA solution for 10 min. Rabbit polyclonal anti-YB-1 (1 : 100) and mouse monoclonal anti-MVP (1 : 50, MVP-37) were incubated for 1 h at room temperature (Schroeijers et al., 2001; Janz et al., 2002) . Biotinylated swine-anti-rabbit or rabbit-anti-mouse serum (1 : 100 and 1 : 300, Dako, Kopenhagen, Denmark) and HRP-labeled streptavidin (1 : 500, Dako) were used as secondary reagents. Color development was with 0.4 mg/ml amino-ethyl-carbazole and 0.02% H 2 O 2 as a chromogen. Sections incubated with the respective isotype antibody served as controls.
Statistical analysis
Levels of statistical significance were evaluated using the nonparametric two-sided Mann-Whitney rank sum test.
